In human CD4+ T cells, miR-138 represses PD-1, CTLA-4, and FoxP3 expression, and in vivo administration of miR-138 mimics to tumor-bearing mice led to enhanced T-cell–mediated tumor immunity and survival (85). Here, CTLA4 is linked to neoplasm.